
    
      Open-label study in two parallel groups of 20 healthy subjects each. Group A assessed the
      effect of CBZ on ESL pharmacokinetics, and Group B assessed the effect of ESL on CBZ
      pharmacokinetics. Each patient participated in the study for approximately 9 weeks. The
      clinical portion of the study was completed in approximately 3 months. Subjects received the
      treatments during 35 days.
    
  